These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 35013322)

  • 1. Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment.
    Qi Z; Xu Z; Zhang L; Zou Y; Li J; Yan W; Li C; Liu N; Wu H
    Nat Commun; 2022 Jan; 13(1):182. PubMed ID: 35013322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kα/β/δ Inhibitor BAY1082439.
    Zou Y; Qi Z; Guo W; Zhang L; Ruscetti M; Shenoy T; Liu N; Wu H
    Mol Cancer Ther; 2018 Oct; 17(10):2091-2099. PubMed ID: 30045927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer.
    Yang Y; Bai Y; He Y; Zhao Y; Chen J; Ma L; Pan Y; Hinten M; Zhang J; Karnes RJ; Kohli M; Westendorf JJ; Li B; Zhu R; Huang H; Xu W
    Clin Cancer Res; 2018 Feb; 24(4):834-846. PubMed ID: 29167276
    [No Abstract]   [Full Text] [Related]  

  • 4. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
    Han MG; Jang BS; Kang MH; Na D; Kim IA
    Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas.
    Aslan K; Turco V; Blobner J; Sonner JK; Liuzzi AR; Núñez NG; De Feo D; Kickingereder P; Fischer M; Green E; Sadik A; Friedrich M; Sanghvi K; Kilian M; Cichon F; Wolf L; Jähne K; von Landenberg A; Bunse L; Sahm F; Schrimpf D; Meyer J; Alexander A; Brugnara G; Röth R; Pfleiderer K; Niesler B; von Deimling A; Opitz C; Breckwoldt MO; Heiland S; Bendszus M; Wick W; Becher B; Platten M
    Nat Commun; 2020 Feb; 11(1):931. PubMed ID: 32071302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells.
    Limagne E; Nuttin L; Thibaudin M; Jacquin E; Aucagne R; Bon M; Revy S; Barnestein R; Ballot E; Truntzer C; Derangère V; Fumet JD; Latour C; Rébé C; Bellaye PS; Kaderbhaï CG; Spill A; Collin B; Callanan MB; Lagrange A; Favier L; Coudert B; Arnould L; Ladoire S; Routy B; Joubert P; Ghiringhelli F
    Cancer Cell; 2022 Feb; 40(2):136-152.e12. PubMed ID: 35051357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
    Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
    Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
    Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
    Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of Wnt/β-catenin signaling promotes immune evasion via the β-catenin/IKZF1/CCL5 axis in hepatocellular carcinoma.
    Huang Y; Peng M; Yu W; Li H
    Int Immunopharmacol; 2024 Sep; 138():112534. PubMed ID: 38941667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.
    Moeini S; Saeidi M; Fotouhi F; Mondanizadeh M; Shirian S; Mohebi A; Gorji A; Ghaemi A
    Arch Virol; 2017 Feb; 162(2):333-346. PubMed ID: 27699512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TGF-β inhibition can overcome cancer primary resistance to PD-1 blockade: A mathematical model.
    Siewe N; Friedman A
    PLoS One; 2021; 16(6):e0252620. PubMed ID: 34061898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3Kαδ Inhibitor Combined With Radiation Enhances the Antitumor Immune Effect of Anti-PD1 in a Syngeneic Murine Triple-Negative Breast Cancer Model.
    Chang WI; Han MG; Kang MH; Park JM; Kim EE; Bae J; Ahn S; Kim IA
    Int J Radiat Oncol Biol Phys; 2021 Jul; 110(3):845-858. PubMed ID: 33642128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.
    Sackmann Sala L; Boutillon F; Menara G; De Goyon-Pélard A; Leprévost M; Codzamanian J; Lister N; Pencik J; Clark A; Cagnard N; Bole-Feysot C; Moriggl R; Risbridger GP; Taylor RA; Kenner L; Guidotti JE; Goffin V
    J Pathol; 2017 Sep; 243(1):51-64. PubMed ID: 28603917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8
    Carnevalli LS; Sinclair C; Taylor MA; Gutierrez PM; Langdon S; Coenen-Stass AML; Mooney L; Hughes A; Jarvis L; Staniszewska A; Crafter C; Sidders B; Hardaker E; Hudson K; Barry ST
    J Immunother Cancer; 2018 Dec; 6(1):158. PubMed ID: 30587236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells.
    Exposito F; Redrado M; Houry M; Hastings K; Molero-Abraham M; Lozano T; Solorzano JL; Sanz-Ortega J; Adradas V; Amat R; Redin E; Leon S; Legarra N; Garcia J; Serrano D; Valencia K; Robles-Oteiza C; Foggetti G; Otegui N; Felip E; Lasarte JJ; Paz-Ares L; Zugazagoitia J; Politi K; Montuenga L; Calvo A
    Cancer Res; 2023 Aug; 83(15):2513-2526. PubMed ID: 37311042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting TREM2 on tumor-associated macrophages enhances immunotherapy.
    Binnewies M; Pollack JL; Rudolph J; Dash S; Abushawish M; Lee T; Jahchan NS; Canaday P; Lu E; Norng M; Mankikar S; Liu VM; Du X; Chen A; Mehta R; Palmer R; Juric V; Liang L; Baker KP; Reyno L; Krummel MF; Streuli M; Sriram V
    Cell Rep; 2021 Oct; 37(3):109844. PubMed ID: 34686340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy.
    Anker JF; Naseem AF; Mok H; Schaeffer AJ; Abdulkadir SA; Thumbikat P
    Nat Commun; 2018 Apr; 9(1):1591. PubMed ID: 29686284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.